Miscellaneous ePI Test
0.1.0 - CI Build

Miscellaneous ePI Test, published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cander2/epi-test/ and changes regularly. See the Directory of published versions

: Regulated Authorization - Herceptin (trastazumab) 150 mg for Intravenous Use - JSON Representation

Raw json | Download


{
  "resourceType" : "RegulatedAuthorization",
  "id" : "authsimvastatin20",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: RegulatedAuthorization</b><a name=\"authsimvastatin20\"> </a><a name=\"hcauthsimvastatin20\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource RegulatedAuthorization &quot;authsimvastatin20&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-RegulatedAuthorization-uv-epi.html\">RegulatedAuthorization (ePI)</a></p></div><p><b>identifier</b>: <code>https://pmda-approvalandlicenseno/</code>/21300AMY00128\u00a0(use:\u00a0official)</p><p><b>subject</b>: <a href=\"MedicinalProductDefinition-medprodsimvastatin20.html\">MedicinalProductDefinition/medprodsimvastatin20</a></p><p><b>type</b>: Marketing Authorisation <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (#/#100000072062)</span></p><p><b>region</b>: Japan <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#jp)</span></p><p><b>status</b>: Active <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://hl7.org/fhir/R5/codesystem-publication-status.html\">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2002-08-01 13:28:17+0000</p><p><b>holder</b>: <a href=\"Organization-orgohara.html\">Organization/orgohara</a> &quot;Ohara Pharmaceutical Co., Ltd.&quot;</p></div>"
  },
  "identifier" : [
    {
      "use" : "official",
      "system" : "https://pmda-approvalandlicenseno/",
      "value" : "21300AMY00128"
    }
  ],
  "subject" : [
    {
      🔗 "reference" : "MedicinalProductDefinition/medprodsimvastatin20"
    }
  ],
  "type" : {
    "coding" : [
      {
        "system" : "https://spor.ema.europa.eu/rmswi/",
        "code" : "/#100000072062"
      }
    ],
    "text" : "Marketing Authorisation"
  },
  "region" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "jp"
        }
      ],
      "text" : "Japan"
    }
  ],
  "status" : {
    "coding" : [
      {
        "system" : "http://hl7.org/fhir/publication-status",
        "code" : "active"
      }
    ],
    "text" : "Active"
  },
  "statusDate" : "2002-08-01T13:28:17Z",
  "holder" : {
    🔗 "reference" : "Organization/orgohara"
  }
}